10β-Amino-19-nor-Δ⁴-androsten-3,17-dion | 15184-49-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 10β-Amino-19-nor-Δ⁴-androsten-3,17-dion
• 英文别名: 19-Azaandrostenedione；(8S,9S,10S,13S,14S)-10-amino-13-methyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-3,17-dione
• CAS: 15184-49-3
• 化学式: C₁₈H₂₅NO₂
• 分子量: 287.402
• InChiKey: VCRGGMFLPVASGG-FTAMUGHTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  21
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  60.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  10β-isocyanato-4-estrene-3,17-dione 在 溶剂黄146 作用下， 反应 4.25h， 以51.6%的产率得到10β-Amino-19-nor-Δ⁴-androsten-3,17-dion
  参考文献：
  名称：

  19-氮杂-和19-氨基雄烯二酮类似物作为潜在的芳香化酶抑制剂的合成和评估。

  摘要：

  合成了19-氮杂雄烯二酮（10β-氨基-4-雌烯-3,17-二酮，2）和19-氨基-4-雄烯-3,17-二酮（3）的衍生物作为芳香化酶的潜在抑制剂（雌激素合成酶） ）。通过Curtius重排，由3，17-二氧代-4-androsten-19-oic酸（5）合成化合物2及其衍生物。由中间体3,17-双（亚乙基二氧基）-5-androsten-19-al肟（14）合成3的衍生物，该中间体用阮内镍还原为相应的胺（16）。但是，尝试通过几种不同的方法从16种化合物中合成3种母体化合物是不成功的。在human水测试中检测芳香化酶的抑制活性，以人胎盘微粒体为酶源，以[1-3H] -androst-4-ene-3,17-dione（83％3H 1 beta）为酶源。基板。

  DOI：

  10.1021/jm00372a005

文献信息

• Methods and compositions for the treatment of estrogen-dependent hyperproliferative uterine disorders
  申请人：Wang Changjin

  公开号：US20100087402A1

  公开（公告）日：2010-04-08

  The present invention relates to the treatment of estrogen-dependent hyperproliferative uterine disorders including endometriosis, uterine fibroids, endometrial hyperplasia, uterine cancer, and their related symptoms by intravaginally administering at least two active agents selected from an aromatase inhibitor, an antiinflammatory agent, and a uterine-selective estrogen receptor antagonist. This combination therapy reduces local estrogen production, blocks local estrogen action, and suppresses inflammation locally, resulting in starvation of the estrogen-dependent diseased tissues, relief of related symptoms, and retardation of disease progression. Intravaginal delivery maximizes local inhibition of estrogen production without significantly affecting systemic circulating estrogen levels. This results in enhanced clinical efficacy and reduced side effects.

  本发明涉及治疗依赖雌激素的子宫过度增生性疾病，包括子宫内膜异位症、子宫肌瘤、子宫内膜增生、子宫癌及其相关症状，通过阴道给药至少两种活性药物，所选药物包括芳香化酶抑制剂、抗炎药和子宫选择性雌激素受体拮抗剂。这种联合疗法降低了局部雌激素产生，阻断了局部雌激素作用，并在局部抑制了炎症，导致对依赖雌激素的疾病组织的饥饿，缓解相关症状，延缓疾病进展。阴道给药最大限度地抑制了局部雌激素产生，而不显著影响全身循环雌激素水平。这导致增强的临床疗效和减少的副作用。
• Ponsold; Schade; Wunderwald, Journal fur praktische Chemie (Leipzig 1954), 1975, vol. 317, # 2, p. 298 - 306
  作者：Ponsold、Schade、Wunderwald

  DOI：——

  日期：——
• Methods and Compositions for the Treatment of Estrogen-Dependent Hyperproliferative Uterine Disorders
  申请人：Vivus, Inc.

  公开号：US20140080794A1

  公开（公告）日：2014-03-20

  The present invention relates to the treatment of estrogen-dependent hyperproliferative uterine disorders including endometriosis, uterine fibroids, endometrial hyperplasia, uterine cancer, and their related symptoms by intravaginally administering at least two active agents selected from an aromatase inhibitor, an antiinflammatory agent, and a uterine-selective estrogen receptor antagonist. This combination therapy reduces local estrogen production, blocks local estrogen action, and suppresses inflammation locally, resulting in starvation of the estrogen-dependent diseased tissues, relief of related symptoms, and retardation of disease progression. Intravaginal delivery maximizes local inhibition of estrogen production without significantly affecting systemic circulating estrogen levels. This results in enhanced clinical efficacy and reduced side effects.